Nora de Bode , Emese Kroon , Sharon R. Sznitman , Janna Cousijn
{"title":"The differential effects of medicinal cannabis on mental health: A systematic review","authors":"Nora de Bode , Emese Kroon , Sharon R. Sznitman , Janna Cousijn","doi":"10.1016/j.cpr.2025.102581","DOIUrl":null,"url":null,"abstract":"<div><div>The use of medicinal cannabis to improve mental health is increasing globally, both in clinical settings and through self-medication. This involves a variety of products containing ∆9-tetrahydrocannabinol (THC), cannabidiol (CBD), THC + CBD combinations, or derivatives. This review provides an up-to-date overview of the positive and negative effects of medicinal cannabis on mental health diagnoses and related symptoms of the Diagnostic and Statistical Manual of Mental Disorders 5th Edition. Searches in PubMed, PsycInfo, Embase, and the Cochrane Library (October 2023 and July 2024) identified 18,341 studies, of which 49 controlled studies from 15 different countries were included. All studies focused on treatment-seeking participants using medicinal cannabis for (symptoms of) their mental health diagnosis. Included diagnoses were anxiety disorders, tic disorders, autism spectrum disorder, attention-deficit hyperactivity disorder, obsessive-compulsive disorders, anorexia nervosa, schizophrenia, psychosis, substance use disorders, insomnia, and bipolar disorders. Varying product compositions showed different effects. Most consistently, high doses of CBD were followed by some acute relief in anxiety, while CBD + THC combinations alleviated withdrawal in cannabis use disorder and improved sleep. In clinical trials, THC was associated most with dose-dependent adverse events and, in some cases, deterioration of primary study outcomes, e.g., in psychosis. In naturalistic studies, participants who used THC reported symptom improvement following usage. Risks of bias across studies were prevalent, and no study found long-lasting medicinal effects or improvement. Overall, medicinal cannabis may provide short-term relief for certain symptoms but is not a cure or without mental health risks.</div></div>","PeriodicalId":48458,"journal":{"name":"Clinical Psychology Review","volume":"118 ","pages":"Article 102581"},"PeriodicalIF":12.2000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Psychology Review","FirstCategoryId":"102","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0272735825000479","RegionNum":1,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/29 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PSYCHOLOGY, CLINICAL","Score":null,"Total":0}
引用次数: 0
Abstract
The use of medicinal cannabis to improve mental health is increasing globally, both in clinical settings and through self-medication. This involves a variety of products containing ∆9-tetrahydrocannabinol (THC), cannabidiol (CBD), THC + CBD combinations, or derivatives. This review provides an up-to-date overview of the positive and negative effects of medicinal cannabis on mental health diagnoses and related symptoms of the Diagnostic and Statistical Manual of Mental Disorders 5th Edition. Searches in PubMed, PsycInfo, Embase, and the Cochrane Library (October 2023 and July 2024) identified 18,341 studies, of which 49 controlled studies from 15 different countries were included. All studies focused on treatment-seeking participants using medicinal cannabis for (symptoms of) their mental health diagnosis. Included diagnoses were anxiety disorders, tic disorders, autism spectrum disorder, attention-deficit hyperactivity disorder, obsessive-compulsive disorders, anorexia nervosa, schizophrenia, psychosis, substance use disorders, insomnia, and bipolar disorders. Varying product compositions showed different effects. Most consistently, high doses of CBD were followed by some acute relief in anxiety, while CBD + THC combinations alleviated withdrawal in cannabis use disorder and improved sleep. In clinical trials, THC was associated most with dose-dependent adverse events and, in some cases, deterioration of primary study outcomes, e.g., in psychosis. In naturalistic studies, participants who used THC reported symptom improvement following usage. Risks of bias across studies were prevalent, and no study found long-lasting medicinal effects or improvement. Overall, medicinal cannabis may provide short-term relief for certain symptoms but is not a cure or without mental health risks.
期刊介绍：
Clinical Psychology Review serves as a platform for substantial reviews addressing pertinent topics in clinical psychology. Encompassing a spectrum of issues, from psychopathology to behavior therapy, cognition to cognitive therapies, behavioral medicine to community mental health, assessment, and child development, the journal seeks cutting-edge papers that significantly contribute to advancing the science and/or practice of clinical psychology.
While maintaining a primary focus on topics directly related to clinical psychology, the journal occasionally features reviews on psychophysiology, learning therapy, experimental psychopathology, and social psychology, provided they demonstrate a clear connection to research or practice in clinical psychology. Integrative literature reviews and summaries of innovative ongoing clinical research programs find a place within its pages. However, reports on individual research studies and theoretical treatises or clinical guides lacking an empirical base are deemed inappropriate for publication.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
